February 18, 2022
An update on HPTN 083, the study that established that PrEP given as an injection every two months had superior efficacy to a daily pill in gay and bisexual men and transgender women, was presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI 2022).
Four and a half years of data are now available. The efficacy of cabotegravir injections relative to oral PrEP using tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) remained almost unchanged. People taking the injections had only a third as many HIV infections as people taking the pills: an overall efficacy over TDF/FTC of 66%, compared with 68% reported last year from the blinded part of the study. Adherence was lower in the unblinded phase, but to both cabotegravir and TDF/FTC.
Read the full article HERE
